FB Pixel no scriptMabwell completes Hong Kong IPO
MENU
KrASIA
Apr
30

Mabwell completes Hong Kong IPO

just now
Mabwell Bioscience completed its dual listing on the Hong Kong Stock Exchange on April 28. The company previously secured a USD 600 million licensing deal with Alphabet subsidiary Calico Life Sciences. It reported 2025 revenue of RMB 658.7 million, up 230% YoY.
Share

Latest Pulses

See All

Most Recent